Search PubMed⌕ Search

PubMed · 6887898

Recent developments in corticoid synthesis.

Abstract

In an attempt to improve the industrial manufacture of corticoids starting from desoxycholic acid, two major tasks had to be accomplished: (1) selective transposition of a 12 alpha-oxygen function to the 11-position. (2) Degradation of the side chain by three carbon atoms. The most convenient solution to the first problem included protection of the 3 alpha-hydroxyl, then dehydrating the 12 alpha-alcohol via its mesylate, and treatment of the resulting delta 11-12-alkene with PDC and iodine, to obtain the 12 alpha-iodo-11-ketone in very high yield. After reductive dehalogenation and saponification, the resulting acid proved to be suitable for solving our second problem. Oxidative decarboxylation with lead tetraacetate leads to an olefin, the double bond of which could be shifted along the side chain to produce the corresponding delta 20-22-isomer. Ozonolytic cleavage of the C--C double bond in this position made the 20-ketone 19 readily accessible. The latter plays a key role in the production of various corticoid drugs, since most of them are derived from this very compound, e.g. cortisol.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Do-Trong, W Kreiser, E Strube. 1983. Recent developments in corticoid synthesis.. https://doi.org/10.1016/0022-4731(83)90012-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗